bioAffinity Technologies Presents CyPath Lung Test at American Cancer Society Roundtable
ByAinvest
Wednesday, Dec 3, 2025 8:00 am ET1min read
BIAF--
bioAffinity Technologies' noninvasive CyPath Lung test will be showcased at the American Cancer Society's National Lung Cancer Roundtable. The test successfully identified Stage 1A lung cancer in three patients with atypical and diagnostically challenging presentations. Chief Medical Officer Gordon Downie will present a poster highlighting the cases, demonstrating the test's ability to provide clarity and actionable results in real-world lung nodule practice.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet